Cosentyx (secukinumab subcutaneous injection – Novartis) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has tried at least one other therapy such as intralesional or oral corticosteroids, systemic antibiotics, or isotretinoin
• Medication is prescribed by or in consultation with a dermatologist

Reauthorization criteria

• Patient has been established on Cosentyx subcutaneous for at least 3 months
• When assessed by an objective measure, patient experienced a beneficial clinical response from baseline
• Compared with baseline, patient experienced improvement in ≥ 1 symptom such as decreased pain or drainage of lesions, nodules, or cysts

Approval duration

3 months initial, 1 year reauth